兆科眼科(06622.HK)滴眼液產品關鍵第三期臨牀試驗達預設主要研究終點
兆科眼科(06622.HK)公佈,旗下候選仿製藥「鹽酸左倍他洛爾滴眼液」的關鍵第三期臨牀試驗已達到預設主要研究終點,與基線比較,眼壓於第8個星期有所降低。
公司現正開發鹽酸左倍他洛爾作爲鹽酸倍他洛爾滴眼液的仿製藥,該產品爲用於降低原發性開角型青光眼或高眼壓症患者眼壓的腎上腺素受體拮抗劑。
兆科眼科計劃於2022年上半年爲鹽酸左倍他洛爾滴眼液向國家藥品監督管理局提交新藥上市申請,預期於2023年獲批,並計劃於取得監管批準後自行生產該產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.